These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy. Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353 [TBL] [Abstract][Full Text] [Related]
5. Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies. Pecoraro A; Ricci S; Vultaggio A; Boggia GM; Spadaro G; Clin Drug Investig; 2020 Mar; 40(3):279-286. PubMed ID: 32036588 [TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Hizentra® in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. Jolles S; Rojavin MA; Lawo JP; Nelson R; Wasserman RL; Borte M; Tortorici MA; Imai K; Kanegane H J Clin Immunol; 2018 Nov; 38(8):864-875. PubMed ID: 30415311 [TBL] [Abstract][Full Text] [Related]
7. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin. Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Experience of Subcutaneous Immunoglobulin Therapy in Pediatric Primary Immunodeficient Patients with Low and Normal Body Weight. Gul Y; Kapakli H; Guner SN; Alan HB; Hazar E; Keles S; Reisli I J Clin Immunol; 2022 Jan; 42(1):64-71. PubMed ID: 34617265 [TBL] [Abstract][Full Text] [Related]
9. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency. Gupta S; Kobayashi RH; Litzman J; Cherwin L; Hoeller S; Kreuwel H Expert Rev Clin Immunol; 2023 Jan; 19(1):7-17. PubMed ID: 36346032 [TBL] [Abstract][Full Text] [Related]
11. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of subcutaneous immunoglobulin replacement therapy in Iranian patients with primary immunodeficiencies. Shabaninejad H; Asgharzadeh A; Rezapour A; Rezaei N Med J Islam Repub Iran; 2017; 31():94. PubMed ID: 29951395 [No Abstract] [Full Text] [Related]
13. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes. Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O Allergy Asthma Clin Immunol; 2022 Dec; 18(1):110. PubMed ID: 36566213 [TBL] [Abstract][Full Text] [Related]
14. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies. Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705 [TBL] [Abstract][Full Text] [Related]
15. Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency. Sidhu J; Rojavin M; Pfister M; Edelman J Biol Ther; 2014 Dec; 4(1-2):41-55. PubMed ID: 25118975 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of hizentra®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. Borte M; Pac M; Serban M; Gonzalez-Quevedo T; Grimbacher B; Jolles S; Zenker O; Neufang-Hueber J; Belohradsky B J Clin Immunol; 2011 Oct; 31(5):752-61. PubMed ID: 21674136 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Jolles S; Sleasman JW Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653 [TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Hizentra® Following Pediatric Hematopoietic Cell Transplant for Treatment of Primary Immunodeficiencies. Patel NC; Torgerson T; Thakar MS; Younger MEM; Sriaroon P; Pozos TC; Buckley RH; Morris D; Vilkama D; Heimall J J Clin Immunol; 2023 Oct; 43(7):1557-1565. PubMed ID: 37266769 [TBL] [Abstract][Full Text] [Related]
19. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin. Ness S Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515 [TBL] [Abstract][Full Text] [Related]
20. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada. Gerth WC; Betschel SD; Zbrozek AS Allergy Asthma Clin Immunol; 2014; 10(1):23. PubMed ID: 24872821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]